news
Study finds Keytruda® improves overall survival in HCC patients
The data adds to the body of evidence relating to the use of Keytruda® as a monotherapy in second-line HCC post sorafenib.
List view / Grid view
hepatocellular carcinoma (HCC)
news
Imfinzi™ plus tremelimumab: “unprecedented survival” in unresectable liver cancer
Almost a third of unresectable hepatocellular carcinoma patients were alive at three years on tremelimumab and Imfinzi regimen.
news
Imfinzi™ improves liver cancer survival in Phase III trial
Imfinzi (durvalumab) demonstrated a meaningful overall survival (OS) benefit versus sorafenib as a first-line treatment for liver cancer.
news
Novel ionic liquid enables uniform chemotherapy delivery in solid tumours
Co-injecting doxorubicin with LATTE, a novel ionic liquid formulation, resulted in uniform chemotherapy delivery and successful ablation in solid tumours.
news
Phenformin-mTOR inhibitor combination shows promise in HCC
A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival...
news
FDA grants two orphan drug designations for HCC
The FDA has granted two orphan drug designations for T cell therapy products for the treatment of hepatocellular carcinoma...
news
Nexavar receives final appraisal for primary liver cancer
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
news
Bayer receives EU approval for Regorafenib
Bayer have announced the European Commission has granted marketing authorisation for Stivarga...
news
SIRT is better tolerated than sorafenib, but doesn’t increase overall survival in HCC
28 April 2017 | By Niamh Marriott, Junior Editor
Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179)...
news
BTG receives CE mark certification for radiopaque drug-eluting bead
6 April 2017 | By Niamh Marriott, Junior Editor
BTG has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead...
news
FDA grants priority review for Bayer’s liver cancer treatment
4 January 2017 | By Niamh Louise Marriott, Digital Editor
The application is based on data from the placebo-controlled Phase III trial which investigated the drug as a second line treatment...
news
RedHill Biopharma commences Phase II hepatocellular carcinoma study
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
RedHill Biopharma, will shortly commence a study evaluating yeliva (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), pending final...
news
Regorafenib increases overall survival in hepatocellular carcinoma study
29 June 2016 | By Victoria White, Digital Content Producer
Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced...